A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT03375164 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
4
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sarepta Therapeutics, Inc.